DB-1303

BioNTech, DualityBio, Breast Cancer, DB-1303, HER2-low breast cancer, Clinical trial initiation, Antibody-drug conjugate

BioNTech and DualityBio Advance Novel HER2-low Breast Cancer Drug to Phase III Trial

Anika Sharma

BioNTech, the renowned name behind the COVID-19 vaccine breakthrough, is venturing into uncharted territory with its licensed antibody-drug conjugate (ADC), ...